Iressa : first angiogenesis inhibitor approved for the treatment of advanced NSCLC

Expert Rev Anticancer Ther. 2003 Jun;3(3):257. doi: 10.1586/14737140.3.3.257.
No abstract available

Publication types

  • News

MeSH terms

  • Angiogenesis Inhibitors / adverse effects
  • Angiogenesis Inhibitors / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Drug Approval / legislation & jurisprudence
  • Gefitinib
  • Humans
  • Lung Neoplasms / drug therapy*
  • Quinazolines / adverse effects
  • Quinazolines / therapeutic use*
  • United States

Substances

  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Quinazolines
  • Gefitinib